#EXIT
PANDEMIC
TET RAY
INTERNATIONAL
HEALTH REGULATIONS
4
Corruptions and Conflicts of Interest!
WHO: Corruption and Conflict of Interest?
https://andrewharmer.org/2018/05/27/ac-vc-the-shock-of-who-funding/
a
trustWHO
WHO plan 10 years of Pandemics
Dr Marion Koopmans
WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO)
https://apps.who.int/iris/rest/bitstreams/1414639/retrieve
WHO/Gates Foundation: Decade of Vaccines Conflicts
The Council comprises of the Director-General of the WHO, the Director of NIAID, the Director of UNICEF, the President of Gates Foundation Global Health, and the Chair of the African Malaria Alliance
https://www.gatesfoundation.org/Ideas/Media-Center/Press-Releases/2010/01/Bill-and-Melinda-Gates-Pledge-$10-Billion-in-Call-for-Decade-of-Vaccines
https://www.gatesfoundation.org/Ideas/Media-Center/Press-Releases/2010/12/Global-Health-Leaders-Launch-Decade-of-Vaccines-Collaboration
https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/global-vaccine-action-plan
b
“
The WHO is the World Vaccination Organization
Dr Astrid Stuckelberger WHO Insider and Whistleblower
SAGE | |
Strategic Advisory Group of Experts on immunization | |
Global policies and strategies on all vaccines, vaccine-preventable diseases and technology | |
WHO-IVB | |
WHO Immunization, Vaccinations and Biologicals Regulations | |
Advise D-G on Vaccine Regulations | |
Global Vaccine Action Plan (GVAP) | ||
Decade of Vaccines (2011–2020) | ||
Funder |
To immunize more people, from infants to seniors, with a greater range of vaccines
PSPQ-SC | |
The Programmatic Suitability of Prequalified Vaccines Standing Committee | |
Ensures continuing compliance with specifications and established standards of quality | |
IVIR-AC | |
Immunization and Vaccines Related Implementation Research Advisory Committee | |
Vaccine value assessments, research, effectiveness and impact studies | |
IPAC | ||
Immunization Practices Advisory Committee | ||
Strengthen GVAP vaccine service delivery | ||
EPI | |
Expanded Programme on Immunization | |
Assessment - strengths and weaknesses of Immunization programmes | |
ECBS | |
Expert Committee on Biological Standardization | |
Establish guidelines for manufacturing, licensing and control of vaccines, blood products and related in vitro diagnostic tests and biotechnology products | |
GACVS | |
Global Advisory Committee on Vaccine Safety | |
Scientific advice to WHO on vaccine safety | |
PDVAC | |
Product Development for Vaccines Advisory Committee | |
Recommendations infectious disease pathogens, associated vaccine and monoclonal antibody product development | |
Developing Countries Vaccine Manufacturers Network |
Strengthen vaccine manufacturers technology transfer initiatives |
WHO EMP | |
WHO Essential Medicines and Health Products Price | |
Sets international standards for the manufacturing and regulation and harmonization aligned with SDG | |
VPPAG
VP-WG | |
Vaccine Prioritization Working Group | |
Evaluate candidate COVID-19 vaccines for the WHO international Solidarity Trial Vaccines | |
Vaccine Presentation and Packaging Advisory Group
Recommendations vaccine formulations, labelling, temp stability
Pandemic Influenza Preparedness Framework
WHO is in the Vaccine Business – Conflicts of Interest
Sponsors
Whistleblower exposes the corruption of the WHO, Bill Gates and GAVI | |
Dr Astrid Stuckelberger WHO Insider and Whistleblower |
41st session of the Corona Investigative Committee |
Whistleblower exposes WHO Corruption
The WHO as a corporate agency by its constitution can direct governments, their health ministries, as a legal obligation to implement international health regulations as directed by the WHO.
WHO has become a health dictatorship, where the Director-General on his own can decide to sell vaccines, sell the PCR
If Tedros (WHO Director-General) decrees something, all the countries have to obey under law.
In 2017, Bill Gates requested to be part of the executive board of the WHO, like a member state. They even put it to a vote that he be recognised as a member state, which is unprecedented in the constitution.
Swiss Medic (FDA equivalent in Switzerland) have signed an agreement with Bill Gates in collaboration with WHO. I suspect every country has signed similar agreements
41st session of the Corona Investigative Committee
Dr Astrid Stuckelberger WHO Insider and Whistleblower
c
trustWHO
Gates Foundation funding/investment in Covid Vaccine Candidates: Conflicts of Interest
Company | Covid Vaccine Candidate | Type | Value Investment (US$) |
Pfizer/BioNTech | BNT162b2 mRNA | To develop mRNA-based vaccines for infectious diseases | $27,5 million (July 2022) $100 million (May 2022) $4,918,943 (BioNTech 2020) $17,252,854 (2016) |
AstraZeneca | ChAdOx1 nCov-19 | Develop COVID-19 DNA vaccine | $750 million (2020)(20) |
ModernaTX, Inc. | mRNA-1273 | To develop mRNA-based vaccines for infectious diseases | $100 million (future projects upto 2022) $1,051,128 (2019) |
Novavax | NVX-CoV2373 | Purified protein antigen Vaccine development | $15 million (2020) |
CureVac | CVnCoV | mRNA coronavirus vaccine | $52 million (27) |
Icosavax Inc. | IVX-411 | Develop COVID-19 vaccine | $10 million (2020) |
Inovio Pharmaceuticals | INO-4800 | Develop COVID-19 DNA vaccine | $5 million (2020) |
Vir Biotechnology, Inc. | HIV vaccine development | $10 million (2022) $10 million (2021) | |
Merck | Molnupiravir | Antiviral drug | $120 million (2021) |
Gates Foundation funding/investment in WHO: Conflicts of Interest
10
Total Contributions (2020-2021)
Country/ Foundation | Total Contribution | Percentage |
Germany | $1.3 billion | 21.7% |
Gates Foundation/ Gavi | $1.2 billion | 20.3% |
USA | $693 million | 11.9% |
Total | $5.8 billion |
https://www.who.int/about/funding/contributors
WHO funding/investment : Conflicts of Interest
World Health Organisation (WHO) Revenue by Type, 2018 - 2019 Total Funding = $5.624 billion | World Health Organisation (WHO) Revenue by Type, 2022 - 2023 Total Funding = $7.908 billion |
https://www.kff.org/global-health-policy/fact-sheet/the-u-s-government-and-the-world-health-organization/
WHO funding/investment : Conflicts of Interest
https://www.csstimes.pk/world-health-organization-contributing-not-css-essay-material/?lcp_page0=6
Bill & Melinda Gates Foundation
GAVI Alliance
Clinton Health Access Initiative
$375 597 694
$244 540 452
$856 492
$750 000
(2020)
$375 546 744
$187 080 008
$2 197 194
$444 021
$3 906 800
Voluntary contributions by fund and contributor
Contributor
(2021)
(2019)
$226 337 804
$230 120 648
$2 844 154
WHO Funding
80% from voluntary contributions
18% from assessed contribution
45% voluntary contributions (2018 – 2019) from Bill and Melinda Gates Foundation
Fully invested in Covid Industry
https://apps.who.int/gb/ebwha/pdf_files /WHA71/A71_INF2-en.pdf
CDC Foundation
$1 858 347
$402 343
Rockefeller Foundation
$2 514 994
Grand Challenges Canada (BMGF)
Gates Ventures, LLC
$218 000
$310 750
Open Society Foundations
$265 000
$240 000
$161 753
Global Antibiotic Research & Development Partnership (GARDP)
Johnson and Johnson Family of Companies Contribution Fund, Inc.
$258 896
$14 957 229
$149 090
$600 000
Johns Hopkins Bloomberg School of Public Health
Path Vaccine Solutions (PVS)
$161 753
Program for Appropriate Technology In Health (PATH)
$972 455
$345 500
Wellcome Trust
$5 574 180
Global Fund to Fight AIDS, Tuberculosis and Malaria
$29 700 000
$17 745 189
$15 718 411
International Vaccine Institute (IVI)
UNITAID
$317 000
$33 519 000
$38 735 962
$60 000
$18 308 869
$93 592 671
$20 296 997
World Bank
$74 005 754
World Organisation for Animal Health (OIE)
Rotary International
$107 502
Population Action International (PAI)
$14 194
$84 661 438
$287 251
$89 162 889
$370 000
$86 559 824
World Health Organisation: Big Pharma Influence
WHO Contributors | Amount(Percentage) | WHO Contributors | Amount(Percentage) |
Bill and Melinda Gates Foundation | $751M(9.39%) | Johnson & Johnson | $45 000 |
GAVI Alliance | $432M(6.43%) | Johnson & Johnson Companies Contribution Fund | $495 000 |
Wellcome Trust | $7.5M(0.12%) | Gilead Sciences Inc. | $5.3M(0.08%) |
World Bank | $158.1M(2.54%) | Merck & Co. | $277 028(0.04%) |
COVID-19 Solidarity Fund | $85.8M(1.38%) | GlaxoSmithKline | $2M(0.03%) |
United Nations Development Fund (UNDP) | $85.6M(1.38%) | Sanofi-Aventis | $10.8M(0.17%) |
CDC Foundation | $4.8M(0.07%) | Bayer AG | 0.07% |
Gates Ventures | $218 000 | Bristol-Myers Squibb | $143 236 |
Path Vaccine Solutions | $92 568 | Hoffman-La Roche | $4 435 165 |
National Institutes of Health (USA) | $688 000 | Novartis | $1.6M(0.03%) |
Program for Appropriate Technology in Health (PATH) | $972 000(0.02%) | Sandoz AG | $93 458 |
Rockefeller Foundation | $5.6M0.09% | Eisai Co. Ltd | $451 426 |
Open Society Foundations | $265 132 | Ely Lilly & Foundation | |
Clinton Health Access Initiative | $1.2M(0.02%) | ||
Care International | |||
Sabin Vaccine Institute |
*
*
Period 2020 - 2021
*
* * *
** *
*
*
*
* *
* Bill & Melinda Gates Foundation direct investment
* Bill & Melinda Gates Foundation partnerships
http://open.who.int/2018-19/contributors/contributor
WHO Funding: Corruption or Conflict of Interest?
Pharmaceutical Industry donations to WHO (General Fund) | |||||
Contributor | 2017 | 2015 | 2014 | 2013 | 2012 |
Bayer AG | $1,158,060 | ||||
Bristol-Myers Squibb | $215,730 | ||||
GlaxoSmithKline | $7,365,666 | $4,094,000 | $6,158,153 | $8,266,284 | $5,785,000 |
Gilead Sciences | $3,124,450 | ||||
Hoffman-La Roche | $6,628,090 | $2,165 000 | $6,158,153 | $4,806,492 | |
Merck | $510,000 | ||||
Merck Sharp and Dohme Chibret | $1,652,226 | ||||
Novartis | $500,000 | $2,834,000 | $5,300,000 | $4,500,000 | |
Sanofi Pasteur | $9,411,491 | ||||
Sanofi-Aventis | $2,634,963 | ||||
Eisai | $280,000 | ||||
Denka Seiken | $417,324 | ||||
Green Cross Corporation | $294,582 | ||||
Kaketsuken | $417,324 | ||||
Rockefeller Foundation | $748,945 | ||||
https://www.dr-rath-foundation.org/2019/01/world-health-organization-gates-foundation-now-second-largest-funder-after-u-s-government/
WHO – Big Pharma Conflicts of Interest
Pandemic Influenza Preparedness
Period 2020 - 2021
http://open.who.int/2018-19/pip
Vaccine Companies
WHO – Big Pharma Conflicts of Interest
World Health Organization Schedule 5 – In-kind and in-service voluntary contributions For the year ended 31 December 2017 (in US dollars) - GENERAL FUND | |||
Contributor | In-Kind | In-Service | Total |
Bayer AG | 426 335 | 426 335 | |
Merck | 39 176 493 | 39 176 493 | |
GlaxoSmithKline (GSK) | 24 100 186 | 24 100 186 | |
Gilead Sciences Inc. | 1 316 250 | 1 316 250 | |
Johnson and Johnson Family of Companies Contribution Fund, Inc. | 14 006 469 | 14 006 469 | |
Novartis | 4 054 840 | 4 054 840 | |
Eisai Co., Ltd (Japan) | 5 770 735 | 5 770 735 | |
Fondation d’Entreprise Sanofi Espoir | 936 023 | 936 023 | |
https://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_INF2-en.pdf
WHO – Big Pharma Conflicts of Interest
Period 2020 - 2021
http://open.who.int/2018-19/ks
Treachery: Vaccine Hesitancy
WHO identifies
Vaccine hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – threatens to reverse progress made in tackling vaccine-preventable diseases. Vaccination is one of the most cost-effective ways of avoiding disease – it currently prevents 2-3 million deaths a year, and a further 1.5 million could be avoided if global coverage of vaccinations
improved.
https://www.who.int/news-room/feature-stories/ten-threats-to-global-health-in-2019
d
Rather
countries
the Ebola, Covid pandemics – the WHO spends a
Foundation
than
focusing
on
strengthening
health
care outbreaks
in
poor like
–
that
would
help
to
contain
future
amount .
resources
projects
with
of
its
on
disproportionate
the measurable outcomes which benefits the Gates
https://ahrp.org/who-controls-the-who/
WHO’s financial contracts are secretand not open to public scrutiny
“No one should be on a committee developing guidelines if they have links to companies that either produce a product — vaccine or drug — or a medical device or test for a disease. It would be preferable that there are no financial ties when it comes to making big decisions on public health—for example, stockpiling a drug—and that includes if they have a currently funded clinical trial.”
Prof Barbara Mintzes
Professor of evidence-based pharmaceutical policy, School of Pharmacy and Charles Perkins Centre, Faculty of Medicine and Health Lead, Evidence, Policy and Influence Collaborative
https://www.bmj.com/bmj/section-pdf/186584?path=/bmj/340/7759/Feature.full.pdf
No comments:
Post a Comment